We identified up to 8-fold amplifications centering on a minimal common region of chr1:226,474,131-227,148,258, which fully encompasses only three other genes (ITPKB, PSEN2, STUM) in addition to PARP1. In our and the TCGA cohorts of primary tumors, we found a similar frequency of PARP1 gains and amplifications across gBRCA1/2 and sporadic HR-WT breast and ovarian tumors. This evidence concerns the gene PSEN2 and ovarian neoplasm.